Back to mobile site

Piper Sandler Reiterates Overweight Rating on Regeneron Pharma (REGN)

October 29, 2024 4:03 PM EDT Send to a Friend
Piper Sandler analyst Christopher Raymond reiterated an Overweight rating and $1,242.00 price target on Regeneron Pharma (NASDAQ: REGN)The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login